Turning Point Therapeutics Taps Investment Banker Yi Larson as CFO

Turning Point Therapeutics (NASDAQ: [[ticker:TPTX]]) has hired one of the investment bankers who guided it to the public markets earlier this year as its chief financial officer. Yi Larson, a managing director at New York-based investment bank Goldman Sachs (NYSE: [[ticker:GS]]), where she has worked for about 12 years, most recently led its healthcare investment banking business. She will start her role as an executive vice president and CFO at Turning Point on Aug. 26, the company announced Monday.

Turning Point, which raised $191.5 million in its April IPO, is developing precision cancer therapies; its lead drug candidate, repotrectinib, is in Phase 2 testing as a treatment for non-small cell lung cancer and advanced solid tumors.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo